Related Experiment Video
Updated: Aug 7, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Bupropion for treatment of interferon-induced depression
Parviz Malek-Ahmadi1, Elias Ghandour
1Department of Neuropsychiatry, School of Medicine, Health Sciences Center, Texas Tech University, Lubbock, TX 79430-9103, USA. parviz.malekahmadi@ttuhsc.edu
Objective:
To report the effect of bupropion in a patient with interferon (IFN)-induced depression and review the use of antidepressants for treatment of depressive symptoms associated with IFN therapy.
Case Summary:
A 43-year-old white woman with chronic hepatitis C and severe IFN-induced depression was treated with sustained-release bupropion initiated at 150 mg/day for 7 days and 100 mg twice daily thereafter. The dosage was increased again, to 350 mg/day when depressive symptoms recurred. While receiving that dose and continuing IFN treatment, she reported significant improvement in her depressive symptoms without experiencing any adverse effects.
Discussion:
There is limited evidence suggesting that IFNs decrease central serotonergic transmission. There are several published reports on the use of selective serotonin-reuptake inhibitors for the treatment of IFN-induced depression. However, controlled studies are needed to assess the efficacy of serotonergic and noradrenergic antidepressants in IFN-treated patients with depressive symptoms.
Conclusions:
Sustained-release bupropion might be of potential benefit in patients with interferon-induced depression.
More Related Videos
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Mania and Antimanic Drugs: Overview
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Inhibitors of Viral Protein Synthesis

